Nipah virus envelope pseudotyped lentiviruses and methods of their use
AssigneeThe Regents of the University of California
InventorsBenhur Lee, Karina Palomares, Olivier Pernet
Life of this patent
Estimating the term…
Abstract
The present invention relates to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glycoproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatment of cancer or CNS disorders.
Claims17
A Nipah virus (NiV) envelope pseudotyped lentivirus particle comprising Nipah Virus fusion (NiV-F) and Nipah Virus attachment (NiV-G) proteins,
- wherein the NiV-F protein comprises a deletion in its cytoplasmic tail relative to a wild-type NiV-F sequence, wherein the NiV-F protein comprises a cytoplasmic tail lacking amino residues 525-546 of SEQ ID NO:
- 1,
- wherein the NiV-G protein is wild-type NiV-G or is a NiV-G protein that has a cytoplasmic tail truncation comprising a deletion in its cytoplasmic tail relative to wild-type NiV-G sequence,
- and wherein the NiV envelope pseudotyped lentivirus particle has increased viral transduction titer compared to a lentivirus particle pseudotyped with wild-type NiV-F and wild-type NiVG.
Dependencies are inferred from the claim text.